CN1679675A - Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof - Google Patents
Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof Download PDFInfo
- Publication number
- CN1679675A CN1679675A CN 200510002885 CN200510002885A CN1679675A CN 1679675 A CN1679675 A CN 1679675A CN 200510002885 CN200510002885 CN 200510002885 CN 200510002885 A CN200510002885 A CN 200510002885A CN 1679675 A CN1679675 A CN 1679675A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- principal agent
- herba
- inflammatory
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 37
- 206010061218 Inflammation Diseases 0.000 title 1
- 239000006187 pill Substances 0.000 claims abstract description 63
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims abstract description 7
- 206010001093 acute tonsillitis Diseases 0.000 claims abstract description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 101
- 229920001223 polyethylene glycol Polymers 0.000 claims description 101
- 239000003795 chemical substances by application Substances 0.000 claims description 81
- 239000000758 substrate Substances 0.000 claims description 39
- 229920002472 Starch Polymers 0.000 claims description 37
- -1 polyoxyethylene stearate Polymers 0.000 claims description 37
- 235000019698 starch Nutrition 0.000 claims description 37
- 239000008107 starch Substances 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 35
- 229920000858 Cyclodextrin Polymers 0.000 claims description 32
- 239000001116 FEMA 4028 Substances 0.000 claims description 32
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 32
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 32
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 32
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 32
- 229960004853 betadex Drugs 0.000 claims description 32
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 32
- 229920001983 poloxamer Polymers 0.000 claims description 32
- 229960000502 poloxamer Drugs 0.000 claims description 32
- 239000011734 sodium Substances 0.000 claims description 32
- 229910052708 sodium Inorganic materials 0.000 claims description 32
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 31
- 150000002148 esters Chemical class 0.000 claims description 31
- 241000746375 Andrographis Species 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
- 239000001828 Gelatine Substances 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 235000015424 sodium Nutrition 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 208000013403 hyperactivity Diseases 0.000 claims description 6
- 231100000331 toxic Toxicity 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 description 53
- 238000002474 experimental method Methods 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000969 carrier Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000000428 dust Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000000729 antidote Substances 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 241001640034 Heteropterys Species 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A Chuanhuang Xiaoyan dripping pill based on the Chuanhuang xiaoyan tablet for treating acute upper respiratory tract infection, acute tonsillitis, and pharyngolaryngitis is disclosed. Its advantages are high release speed and quickly taking its high curative effect.
Description
Technical field
The present invention relates to a kind of antipyretic and antidote functions that has, the pharmaceutical composition that is used for disease treatments such as hyperactivity of toxic heat such as acute upper respiratory tract infection, acute tonsillitis, pharyngolaryngitis, be particularly related to based on Chinese traditional patent formulation and wear yellow Pianomide, change a social system a kind of drug composition oral dropping pill formulation that forms through dosage form.
Background technology
Wear yellow Pianomide according to what the prescription that provides among the national drug standards WS-11053 (ZD-1053)-2002 and extraction process were prepared from, it is a kind of antipyretic and antidote functions that has, the tablet that is used for disease treatments such as hyperactivity of toxic heat such as acute upper respiratory tract infection, acute tonsillitis, pharyngolaryngitis, through clinical verification for many years, steady quality, determined curative effect is the common drug preparation that clinical and family is used for the treatment of above disease.
Below be the prescription of wearing yellow Pianomide and the extraction process that provides among the drug standard WS-11053 (ZD-1053)-2002:
Prescription: Herba Andrographis 375g, Herba Solidaginis 625g, starch 58g;
Method for making: above two flavor medical materials, Herba Andrographis 100g is ground into fine powder; All the other Herba Andrographis and Herba Solidaginis decoct with water secondary, and 2 hours for the first time, 1.5 hours for the second time, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.14～1.16 (85 ℃), puts cold, adding ethanol is 60% to containing the alcohol amount, stirs, and leaves standstill 48 hours, filter, filtrate is concentrated into the thick paste that relative density is 1.31～1.35 (60～80 ℃), adds above-mentioned Herba Andrographis fine powder and starch, mixing is granulated drying, tabletting, sugar coating or film-coat promptly get 1000.
Appended wearing in the yellow Pianomide description is explained as follows for this sheet:
Nomenclature of drug: wear yellow Pianomide;
Main component: Herba Andrographis, Herba Solidaginis;
Character: this product is a coated tablet, removes coating and shows sepia; Bitter in the mouth.
Function cures mainly: heat-clearing and toxic substances removing; Be used for hyperactivity of toxic heat such as acute upper respiratory tract infection, acute tonsillitis, pharyngolaryngitis.
Usage and consumption: oral, one time 6～8,3 times on the one.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.In addition, conventional peroral dosage form as sheet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
Purpose of the present invention, be to replenish the existing deficiency that is used for the oral drug preparation of disease treatments such as hyperactivity of toxic heat such as acute upper respiratory tract infection, acute tonsillitis, pharyngolaryngitis, a kind of bioavailability height is provided, release fast, quick produce effects, pollution-free in the production, and cheap drug composition oral preparation is worn yellow anti-inflammatory dripping pills.
Involved in the present invention wear yellow anti-inflammatory dripping pills, determine through a large amount of experiment sievings, the extraction process of wearing yellow Pianomide based on Chinese traditional patent formulation, through extracting section technology is adjusted, and cooperation drop pill preparation technology is prepared from.Be prepared by the following technical solutions, can obtain the yellow anti-inflammatory dripping pills of wearing involved in the present invention:
[preparation method]
1. Herba Andrographis, Herba Solidaginis extract thick paste or dry powder, and the fine powder made of a part of Herba Andrographis;
2. substrate---one or more the mixture in pharmaceutically suitable carrier such as Polyethylene Glycol (1000～20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9;
4. according to the given ratio of prescription, accurately take by weighing drug extract and Herba Andrographis fine powder and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～90) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively is in above the 2nd step and is incubated during desired state of temperature, mix homogeneously, place in the water dropper jar of drop pill machine, splash in the condensing agent by water dropper, condensing agent can be any one of liquid paraffin, methyl-silicone oil, vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.
[appendix: a kind of preparation method of Chinese medicine extract]
Herba Andrographis 375g, Herba Solidaginis 625g gets Herba Andrographis 100g earlier, it is standby to be ground into fine powder, and all the other Herba Andrographis and Herba Solidaginis decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, collecting decoction, filter, filtrate is concentrated into the clear paste that relative density is 1.14～1.16 (85 ℃), puts cold, adding ethanol is 60% to containing the alcohol amount, stirs, and leaves standstill 48 hours, filter, filtrate is concentrated into the thick paste that relative density is 1.31～1.35 (60～80 ℃); Through the low-temperature reduced-pressure drying, pulverize again, promptly get dry powder.
Given here is to change according to a kind of preparation method of extract among the drug standard WS-11053 (ZD-1053)-2002 to form, and similarly method is a lot, is not limited to this a kind of method during actual enforcement.
Beneficial effect
Wearing yellow Pianomide according to what the prescription that provides among the national drug standards WS-11053 (ZD-1053)-2002 and extraction process were prepared from, is a kind of heat-clearing and toxic substances removing; The sheet class preparation that is used for symptom treatments such as hyperactivity of toxic heat such as acute upper respiratory tract infection, acute tonsillitis, pharyngolaryngitis, through clinical verification for many years, steady quality, determined curative effect is the common drug preparation that clinical and family is used for the treatment of above disease.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.
In addition, conventional peroral dosage form as sheet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
The yellow anti-inflammatory dripping pills of wearing involved in the present invention is compared with wearing yellow Pianomide, has following beneficial effect:
1. involved in the present invention wear yellow anti-inflammatory dripping pills; utilize surfactant etc. to be substrate; make solid dispersion with extractum that contains active constituents of medicine or dry powder; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases, and substrate is hydrophilic, and medicine is had wetting action; can make that medicine is rapidly molten to loose into microgranule or solution, thereby make the dissolving of medicine and absorb and accelerate.Thereby improved bioavailability, brought into play efficient, quick-acting effects etc.
Compare with the administering mode of traditional oral formulations, exist essential distinction.With the drop pill of solid dispersion technology preparation, can adopt oral, can also sublingual administration, effective ingredient is fully contacted with mucomembranous surface, by the mucomembranous epithelial cell absorption, directly enter blood circulation.Owing to directly enter blood circulation without gastrointestinal tract and liver, avoided first pass effect effectively, also avoided gastrointestinal irritation, thereby it is rapid to have an onset, bioavailability height, characteristics such as side effect is little, and medication is convenient.
2. involved in the present invention wear yellow anti-inflammatory dripping pills, contact promptly with saliva and dissolve rapidly, and absorb by oral mucosa, not only rapid-action, and also the influence of not taken food, promptly all can containing take after meal ante cibum, local application's onset is faster.
3. the yellow anti-inflammatory dripping pills of wearing involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
5. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind.
In sum, make the advantage that yellow anti-inflammatory dripping pills has triple effect (quick-acting, efficient, long-acting), three little (taking dose is little, toxicity is little, side effect little), five convenience (convenient for production, store convenience, convenient transportation, easy to carry, easy to use) of wearing involved in the present invention.
The specific embodiment
Now, be described further with regard to preparation method of wearing yellow anti-inflammatory dripping pills of the present invention with several groups of specific embodiments.
First group: the test of single-matrix
1. according to [appendix: a kind of preparation method of Chinese medicine extract], get Herba Andrographis 375g, Herba Solidaginis 625g, get Herba Andrographis 100g earlier, it is standby to be ground into fine powder, and all the other Herba Andrographis and Herba Solidaginis decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, collecting decoction filtered, filtrate is concentrated into the clear paste that relative density is 1.14～1.16 (85 ℃), put coldly, adding ethanol to the alcohol amount of containing is 60%, stirs, left standstill 48 hours, filter, filtrate is concentrated into the thick paste that relative density is 1.31～1.35 (60～80 ℃), again through the low-temperature reduced-pressure drying, pulverize, it is standby promptly to get principal agent dry powder;
2. substrate: Polyethylene Glycol
(1000～20000), pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9;
4. be prepared according to the process of [preparation method] 4～7 again, promptly can make the yellow anti-inflammatory dripping pills of wearing of various different sizes.
[result of the test]
Test 1: principal agent and different substrates are prepared when 1: 1 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, according to 1: 1 ratio, with principal agent respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
9300, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain principal agent and different substrates, and obtain 15 groups of different experimental results and see Table 1.
Test 2: principal agent and different substrates are prepared when 1: 3 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, according to 1: 3 ratio, with principal agent respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
9300, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain principal agent and different substrates, and obtain 15 groups of different experimental results and see Table 2.
Test 3: principal agent and different substrates are prepared when 1: 9 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, according to 1: 9 ratio, with principal agent respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
9300, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain principal agent and different substrates, and obtain 15 groups of different experimental results and see Table 3.
Second group: the test of mixed-matrix
1. according to [appendix: a kind of preparation method of Chinese medicine extract], get Herba Andrographis 375g, Herba Solidaginis 625g, get Herba Andrographis 100g earlier, it is standby to be ground into fine powder, and all the other Herba Andrographis and Herba Solidaginis decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, collecting decoction filtered, filtrate is concentrated into the clear paste that relative density is 1.14～1.16 (85 ℃), put coldly, adding ethanol to the alcohol amount of containing is 60%, stirs, left standstill 48 hours, filter, filtrate is concentrated into the thick paste that relative density is 1.31～1.35 (60～80 ℃), again through the low-temperature reduced-pressure drying, pulverize, it is standby promptly to get principal agent dry powder;
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. (with g or kg is unit to proportioning, by weight)
3.1 the ratio of composite interstitial substance---polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: Polyethylene Glycol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10,
3.2 mixing principal agent: mixed-matrix weight and=1: 1～1: 9.
4. be prepared according to the process of [preparation method] 4～7 again, promptly can make the yellow anti-inflammatory dripping pills of wearing of various different sizes.
[result of the test]
Test 4: principal agent and mixed-matrix are prepared when 1: 1 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 4.
Test 5: principal agent and mixed-matrix are prepared when 1: 3 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 5.
Test 6: principal agent and mixed-matrix are prepared when 1: 9 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 6.
Test 7: principal agent and mixed-matrix are prepared when 1: 1 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 7.
Test 8: principal agent and mixed-matrix are prepared when 1: 3 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 8.
Test 9: principal agent and mixed-matrix are prepared when 1: 9 the proportioning wears yellow anti-inflammatory dripping pills in qualitative difference in order to observe, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 9.
Test 10: wear yellow anti-inflammatory dripping pills in qualitative difference for what observe that principal agent and mixed-matrix make when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 10.
Test 11: wear yellow anti-inflammatory dripping pills in qualitative difference for what observe that principal agent and mixed-matrix make when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 11.
Test 12: wear yellow anti-inflammatory dripping pills in qualitative difference for what observe that principal agent and mixed-matrix make when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio principal agent is mixed mutually with 4 kinds of different mixed-matrixes again and make evenly, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that principal agent and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 12.
The group practices of table 1 principal agent and single-matrix
(principal agent: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | ????50.0 | ????80 | ????＜30 | ????＞10 | + |
| Polyethylene Glycol 2000 | ????50.0 | ????70 | ????＜30 | ????＞10 | + |
| Polyethylene Glycol 4000 | ????50.0 | ????76 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 6000 | ????50.0 | ????82 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 8000 | ????50.0 | ????79 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 9300 | ????50.0 | ????88 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 10000 | ????50.0 | ????80 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 20000 | ????50.0 | ????80 | ????＜30 | ????＞10 | ++ |
| Polyoxyethylene stearate 40 esters | ????50.0 | ????78 | ????＜30 | ????＞10 | ++ |
| Betacyclodextrin | ????50.0 | ????72 | ????＜30 | ????＞10 | + |
| Poloxamer | ????50.0 | ????79 | ????＜30 | ????＞10 | ++ |
| Carboxymethyl starch sodium | ????50.0 | ????73 | ????＜30 | ????＞10 | + |
| Sodium lauryl sulphate | ????50.0 | ????68 | ????＞30 | ????＞10 | ++ |
| Stearic acid | ????50.0 | ????55 | ????＞30 | ????＞10 | +++ |
| Sodium stearate | ????50.0 | ????54 | ????＞30 | ????＞10 | +++ |
| Glycerin gelatine | ????50.0 | ????55 | ????＞30 | ????＞10 | +++ |
| Lac | ????50.0 | ????52 | ????＞30 | ????＞10 | +++ |
The group practices of table 2 principal agent and single-matrix
(principal agent: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | ????25.0 | ????80 | ????＜30 | ????＞10 | + |
| Polyethylene Glycol 2000 | ????25.0 | ????79 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 4000 | ????25.0 | ????86 | ????＜30 | ????＜10 | ++ |
| Polyethylene Glycol 6000 | ????25.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 8000 | ????25.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 9300 | ????25.0 | ????94 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 1000 | ????25.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 2000 | ????25.0 | ????91 | ????＜30 | ????＜10 | ++ |
| Polyoxyethylene stearate 40 esters | ????25.0 | ????92 | ????＜30 | ????＜10 | ++ |
| Betacyclodextrin | ????25.0 | ????82 | ????＜30 | ????＞10 | ++ |
| Poloxamer | ????25.0 | ????89 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium | ????25.0 | ????80 | ????＜30 | ????＞10 | ++ |
| Sodium lauryl sulphate | ????25.0 | ????77 | ????＜30 | ????＞10 | ++ |
| Stearic acid | ????25.0 | ????73 | ????＞30 | ????＞10 | +++ |
| Sodium stearate | ????25.0 | ????72 | ????＞30 | ????＞10 | +++ |
| Glycerin gelatine | ????25.0 | ????71 | ????＞30 | ????＞10 | +++ |
| Lac | ????25.0 | ????72 | ????＞30 | ????＞10 | +++ |
The group practices of table 3 principal agent and single-matrix
(principal agent: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | ????10.0 | ????80 | ????＜30 | ????＞10 | + |
| Polyethylene Glycol 2000 | ????10.0 | ????83 | ????＜30 | ????＞10 | ++ |
| Polyethylene Glycol 4000 | ????10.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 6000 | ????10.0 | ????94 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 8000 | ????10.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 9300 | ????10.0 | ????89 | ????＜30 | ????＞10 | +++ |
| Polyethylene Glycol 10000 | ????10.0 | ????93 | ????＜30 | ????＜10 | +++ |
| Polyethylene Glycol 20000 | ????10.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Polyoxyethylene stearate 40 esters | ????10.0 | ????93 | ????＜30 | ????＜10 | ++ |
| Betacyclodextrin | ????10.0 | ????88 | ????＜30 | ????＜10 | ++ |
| Poloxamer | ????10.0 | ????92 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium | ????10.0 | ????86 | ????＜30 | ????＜10 | +++ |
| Sodium lauryl sulphate | ????10.0 | ????83 | ????＜30 | ????＞10 | +++ |
| Stearic acid | ????10.0 | ????76 | ????＞30 | ????＞10 | +++ |
| Sodium stearate | ????10.0 | ????77 | ????＞30 | ????＞10 | +++ |
| Glycerin gelatine | ????10.0 | ????74 | ????＞30 | ????＞10 | +++ |
| Lac | ????10.0 | ????73 | ????＞30 | ????＞10 | +++ |
The group practices of table 4 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ????50 | ????85 | ????＜30 | ????＜10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ????50 | ????86 | ????＜30 | ????＜10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ????50 | ????81 | ????＜30 | ????＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ????50 | ????78 | ????＜30 | ????＞10 | + |
The group practices of table 5 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ????25 | ????92 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ????25 | ????93 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ????25 | ????89 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ????25 | ????86 | ????＜30 | ????＞10 | ++ |
The group practices of table 6 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ????10 | ????92 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ????10 | ????92 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ????10 | ????90 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ????10 | ????84 | ????＜30 | ????＞10 | +++ |
The group practices of table 7 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ????50 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ????50 | ????94 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ????50 | ????89 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ????50 | ????83 | ????＜30 | ????＞10 | ++ |
The group practices of table 8 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ????25 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ????25 | ????95 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ????25 | ????92 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ????25 | ????89 | ????＜30 | ????＜10 | ++ |
The group practices of table 9 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ????10 | ????95 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ????10 | ????94 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ????10 | ????91 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ????10 | ????88 | ????＜30 | ????＜10 | +++ |
The group practices of table 10 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ????50 | ????91 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ????50 | ????91 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ????50 | ????89 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ????50 | ????82 | ????＜30 | ????＞10 | +++ |
The group practices of table 11 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ????25 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ????25 | ????93 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ????25 | ????90 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ????25 | ????87 | ????＜30 | ????＜10 | +++ |
The group practices of table 12 principal agent and mixed-matrix
(principal agent: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ????10 | ????94 | ????＜30 | ????＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ????10 | ????93 | ????＜30 | ????＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ????10 | ????91 | ????＜30 | ????＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ????10 | ????90 | ????＜30 | ????＜10 | +++ |
1. can be seen by the result in the table: when the ratio of principal agent and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all comparatively desirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of principal agent and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of principal agent and substrate is 1: 9, though the rounding rate, the ball method of double differences is different and index such as hardness has raising, and is not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly is out of shape, " ++ " expression distortion of firmly pressing, and " +++" expression is indeformable by it.
Claims (7)
1. a drug composition oral preparation that is used for disease treatments such as hyperactivity of toxic heat such as acute upper respiratory tract infection, acute tonsillitis, pharyngolaryngitis is worn yellow anti-inflammatory dripping pills, with Herba Andrographis, Herba Solidaginis is raw material of Chinese medicine, be prepared from a certain proportion of pharmaceutically suitable carrier, wherein:
1.1 Herba Andrographis, Herba Solidaginis extract thick paste or dry powder, and the fine powder made of a part of Herba Andrographis;
1.2 substrate---Polyethylene Glycol
(1000～20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
1.3 proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9.
2. as claimed in claim 1ly wear yellow anti-inflammatory dripping pills, it is characterized in that: described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or Polyethylene Glycol and poloxamer or Polyethylene Glycol and carboxymethyl starch sodium or Polyethylene Glycol and betacyclodextrin; With g or kg is unit, and by weight, its mixed proportion is polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: Polyethylene Glycol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10.
3. any yellow anti-inflammatory dripping pills of wearing as claimed in claim 1 or 2, it is characterized in that: the mixed proportion of described principal agent and substrate is 1: 1～1: 5.
4. as claimed in claim 1ly wear yellow anti-inflammatory dripping pills, it is characterized in that described drug extract extractum or dry powder obtain by the following method: Herba Andrographis 375g, Herba Solidaginis 625g, get Herba Andrographis 100g earlier, it is standby to be ground into fine powder, all the other Herba Andrographis and Herba Solidaginis, decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, collecting decoction, filter, filtrate is concentrated into the clear paste that relative density is 1.14～1.16 (85 ℃), puts coldly, and adding ethanol is 60% to containing alcohol amount, stir, left standstill 48 hours, and filtered, filtrate is concentrated into the thick paste that relative density is 1.31～1.35 (60～80 ℃); Through the low-temperature reduced-pressure drying, pulverize again, promptly get dry powder.
5. preparation method of wearing yellow anti-inflammatory dripping pills is characterized in that being made of following process:
5.1. Herba Andrographis, Herba Solidaginis extract thick paste or dry powder, and the fine powder made of a part of Herba Andrographis;
5.2 substrate---Polyethylene Glycol
(1000,2000,4000,6000,8000,9300,10000,20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
5.3 proportioning---with g or kg is unit, by weight, and principal agent: substrate=1: 1～1: 9;
5.4, accurately take by weighing principal agent and substrate according to the given ratio of prescription, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5.5 adopt homemade or general drop pill machine, and adjust the temperature control system of drop pill machine, make the water dropper temperature heating of drop pill machine and remain on 50 ℃～90 ℃, the temperature cooling of condensing agent also remains on-5 ℃～40 ℃;
5.6 treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively is in above the 2nd step during desired state of temperature, insulation places in the water dropper jar of drop pill machine, splashes into to shrink in the condensing agent by water dropper to be shaped promptly.
6. the preparation method as wearing yellow anti-inflammatory dripping pills as described in the claim 5, it is characterized in that method 5.1 described drug extract extractum or dry powder obtain by the following method: Herba Andrographis 375g, Herba Solidaginis 625g, get Herba Andrographis 100g earlier, it is standby to be ground into fine powder, all the other Herba Andrographis and Herba Solidaginis, decoct with water secondary, 2 hours for the first time, 1.5 hours for the second time, collecting decoction, filter, filtrate is concentrated into the clear paste that relative density is 1.14～1.16 (85 ℃), puts coldly, and adding ethanol is 60% to containing alcohol amount, stir, left standstill 48 hours, and filtered, filtrate is concentrated into the thick paste that relative density is 1.31～1.35 (60～80 ℃); Through the low-temperature reduced-pressure drying, pulverize again, promptly get dry powder.
7. the preparation method as wearing yellow anti-inflammatory dripping pills as described in the claim 5 is characterized in that: method 5.6 described condensing agents are methyl-silicone oils or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510002885 CN1679675A (en) | 2005-01-28 | 2005-01-28 | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510002885 CN1679675A (en) | 2005-01-28 | 2005-01-28 | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1679675A true CN1679675A (en) | 2005-10-12 |
Family
ID=35066681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510002885 Pending CN1679675A (en) | 2005-01-28 | 2005-01-28 | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1679675A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103518912A (en) * | 2013-10-22 | 2014-01-22 | 张家界航空工业职业技术学院 | Traditional Chinese medicinal health-protection tea for treating chronic pharyngitis and preparation method of traditional Chinese medicinal health-protection tea |
| CN107961257A (en) * | 2017-12-04 | 2018-04-27 | 安徽金太阳生化药业有限公司 | A kind of preparation method for wearing yellow antipyretic capsule |
-
2005
- 2005-01-28 CN CN 200510002885 patent/CN1679675A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103518912A (en) * | 2013-10-22 | 2014-01-22 | 张家界航空工业职业技术学院 | Traditional Chinese medicinal health-protection tea for treating chronic pharyngitis and preparation method of traditional Chinese medicinal health-protection tea |
| CN107961257A (en) * | 2017-12-04 | 2018-04-27 | 安徽金太阳生化药业有限公司 | A kind of preparation method for wearing yellow antipyretic capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1297254C (en) | Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof | |
| CN1679675A (en) | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof | |
| CN1660316A (en) | Drop pills preparation in use for treating bronchitis and preparation method | |
| CN1634478A (en) | Tendril-leaved fritillary bulb loquat drop pills and preparation method thereof | |
| CN1634452A (en) | Yin-nourishing lung-heat clearing drop pills | |
| CN1686362A (en) | Hairy holly root drip pill and its preparation method | |
| CN1294902C (en) | Cough and asthma relieving drop pills prepared using dahurian rhododendron leaf | |
| CN1698822A (en) | 'Gansu' dripping pills for treating hepatitis and its preparation method | |
| CN1307978C (en) | Drop pill for diminishing inflammation in four seasons and its preparation method | |
| CN1660364A (en) | 'Lianzhi' anti inflammation drop pill in use for clearing away heat and toxic material and preparation method | |
| CN1301094C (en) | Throat pain relieving anti-inflammation drop pills for treating oral disease and preparation method thereof | |
| CN1284528C (en) | Orally administered dripping pills prepared by hive body | |
| CN1634511A (en) | Fengshining drop pill for treating rheumatism and its preparation method | |
| CN1301095C (en) | 'Yinchai' drop pills for treating cold, fever and cough and preparation method | |
| CN1660374A (en) | 'Shuanghuang' antiphlogistic drop pill in use relieving inflammation and preparation method | |
| CN1634155A (en) | Propolis dripping pills for treating toothache and its preparation method | |
| CN1686479A (en) | Loquat drip pill for treating cough and its preparation method | |
| CN1284530C (en) | Compound tornado drop pills | |
| CN1679669A (en) | Polygala dropping balls and preparation thereof | |
| CN1686381A (en) | Jaundice capillaris drip pill and its preparation method | |
| CN1682817A (en) | Throat dripping pill for clearing away heat and toxic material and its preparing method | |
| CN1698780A (en) | Dripping pills for treating all kinds of rhinitis and its preparation method | |
| CN1679671A (en) | Compound berberine dropping ball and preparation thereof | |
| CN1709413A (en) | Golden gallbladder-normalizing dropping pill for relaxing-liver and normalizing gallbladder, and its preparing method | |
| CN1660371A (en) | Oral drop pills in use for treating diseases of bacterial infection and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |